| Literature DB >> 17504664 |
Herman J Bueving1, Johannes C van der Wouden.
Abstract
It is estimated that viruses play a role in 30% to 80% of asthma exacerbations. Thus, virus vaccination in patients with asthma could play an important role in preventing asthma exacerbations and other complications. Influenza is the only agent for which a routine vaccine is currently available. This article discusses whether influenza vaccination in patients with asthma, based on the available evidence, is justified. Cost-effectiveness of (influenza) vaccination for patients with asthma is questionable. For the other major viruses involved, the present state of affairs is described. Although progress is being made, a vaccine may be available in the near future only for respiratory syncytial virus (RSV). Meanwhile, clinicians and patients should aim for an optimal treatment with the currently available asthma medication.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17504664 PMCID: PMC7088706 DOI: 10.1007/s11882-007-0033-z
Source DB: PubMed Journal: Curr Allergy Asthma Rep ISSN: 1529-7322 Impact factor: 4.806